A BRIEF INTRODUCTION TO BEMPEDOIC ACID

B. SHANMUKI*, D.P. NAGA MANIKANTH*, P. LAKSHMI SOBHITHA, A. LAKSHMI JOSHNA, S. ARAVIND.

Department of pharmacy, Santhiram college of pharmacy, Nandyal, Andhra Pradesh, India.

Abstract: Bampenoic acid is a ACL Inhibitor, lipid lowering agent which is used to treat hypercholesterolemia or mixed dyslipidaemia. This drug is formulated in oral tablet form with dose of 180mg.

Brand name: Nexletol, Nilemdo
Generic name: Bempedoic acid
Company name: ESPERION
Formulations: Tablet
Dosage: 180 mg PO 4 times daily
Year of approval: February 2020 in USA, April 2020 in European union.

Drug properties:
Protein binding: 99.3%
Metabolism: glucuronidation
Elimination half life: 21±11hrs
Excretion: 70% urine, 30% feces

Mechanism of action:
Bempedoic acid is a drug which activated to the thioester with co-enzyme A by the enzyme SLC27A (very long chain acetyl coA synthetase) in the liver. These activated substance inhibits ATP citrate lyase which involved in the liver's biosynthesis of cholesterol upstream of HMG-CoA reductase the enzyme that is blocked by the statins. AMP-activated protein kinase is also activated by these substance, but this effect is not likely relevant in humans.

Side effects:
Muscle spasm, lower back pain, gastrointestinal problems such as diarrhea

Therapeutic uses:
Bempedoic acid in combination with highest tolerated statin therapy which is used to treat hypercholesterolemia for adults with atherosclerotic cardiovascular diseases, heterozygous familial hypercholesterolemia in United States. And given to patients who need additional lowering of LDL cholesterol.
Bempedoic acid is used to treat primary hypercholesterolemia or mixed dyslipidaemia for adult in combination with statin or statins with other lipid lowering therapies and adjuvant to diet in the patients who are statin intolerants, or to the patients who are contraindicated to statins.
Category: ACL Inhibitor, lipid lowering agent

Chemical classification: anti hyperlipidemic drugs (hypolipidemic drugs)

References:

2. Jump up to: "Nilembo EPAR", European Medicines Agency (EMA). 29 January 2020. Retrieved 24 April 2020. This article incorporates text from this source, which is in the public domain.
13. Jump up to: "Drug Trials Snapshots: Nexletol", U.S. Food and Drug Administration. 21 February 2020. Retrieved 27 March 2020. This article incorporates text from this source, which is in the public domain.